Neurodegenerative disorders progress through measurable biological changes long before clinical disability is obvious. Clinically useful predictors fall into fluid, imaging, and functional classes that map to underlying mechanisms such as protein aggregation, synaptic dysfunction, and axonal injury. Evidence from translational research and large cohorts now supports specific markers that forecast faster decline, inform diagnosis, and guide trial enrollment.
Molecular fluid biomarkers
Cerebrospinal fluid measures of amyloid-beta, total tau (t-tau) and phosphorylated tau (p-tau) remain core predictors in Alzheimer disease, with declines in CSF amyloid and rises in p-tau preceding cognitive symptoms. Randall J. Bateman, Washington University in St. Louis, has described temporal relationships showing amyloid changes before tau elevations. Plasma assays for p-tau217 and p-tau181 have emerged as scalable predictors of progression to dementia and correlate with tau PET burden in many cohorts; Kaj Blennow, University of Gothenburg, and Henrik Zetterberg, University of Gothenburg, have published extensively on these blood measures.
Neurofilament light chain (NfL) in CSF and blood is a cross-disease marker of axonal injury that predicts faster clinical deterioration in Alzheimer disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Henrik Zetterberg, University of Gothenburg, has shown that higher plasma NfL associates with more rapid decline and shorter survival in several neurodegenerative syndromes. For synucleinopathies such as Parkinson disease and dementia with Lewy bodies, emerging seed-amplification assays for misfolded alpha-synuclein can improve diagnostic accuracy and may help predict phenoconversion from prodromal states; Byron Caughey, National Institutes of Health, has been a leader in developing these amplification techniques.
Imaging and functional biomarkers
Structural MRI patterns of regional atrophy and longitudinal atrophy rates predict future disability; the AT(N) framework linking amyloid (A), tau (T), and neurodegeneration (N) was articulated in work led by Clifford R. Jack Jr., Mayo Clinic, and provides a practical staging system used in prognostic studies. Molecular PET imaging for amyloid and tau refines risk stratification: amyloid PET positivity increases the likelihood of subsequent tau accumulation and cognitive decline, while tau PET more closely tracks imminent clinical progression. Reisa A. Sperling, Brigham and Women’s Hospital, has combined PET biomarkers with clinical trials to demonstrate how biomarker status modifies treatment effects.
Functional biomarkers such as dopaminergic imaging (DaT-SPECT) and polysomnographic identification of REM sleep behavior disorder predict conversion to Parkinson disease in prodromal cohorts; Ron Postuma, McGill University, has characterized RBD as a strong clinical harbinger of synucleinopathy. In regions with limited PET or CSF capacity, blood-based markers like NfL and plasma p-tau are making prognostication more accessible, but disparities in access and cultural attitudes toward predictive testing shape who benefits from early knowledge.
Biomarkers predict progression by reflecting core disease processes—protein aggregation, synaptic loss, axonal degeneration—and their clinical utility depends on assay standardization, population context, and ethical use. Integrating fluid, imaging, and clinical markers improves accuracy for individuals and trials, while attention to geographic and socioeconomic inequities is essential to ensure equitable access to prognostic advances.